Last reviewed · How we verify

NCT03047772: TEAM-AMI

Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients

Status unknown Phase 2 Last updated 25 January 2018
What this trial tests

Phase 2 trial testing Atorvastatin in Myocardial Infarction in 124 participants. Status unknown.

Timeline
6 March 2018
Primary endpoint
31 December 2018
31 December 2018

Quick facts

Lead sponsorYuejin Yang
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designfactorial
Maskingtriple
Primary purposetreatment
Enrollment124
Start date6 March 2018
Primary completion31 December 2018
Estimated completion31 December 2018

Drugs / interventions tested

Conditions studied

Sponsor

Yuejin Yang — full company profile →

Who can join

Adults 30 to 75, any sex, with Myocardial Infarction or Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The benefit of current stem cell transplantation therapy for myocardial infarction is limited by low survival rate for stem cell. The purpose of this study is to test whether intensive Atorvastatin therapy can improve the outcome of patients with impaired left ventricle function after acute myocardial infarction who underwent intracoronary transfer of autologous bone marrow mesenchymal stem cells.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review.
    Margiana R, Margiana R, Margiana R, Markov A, et al · · 2022 · cited 263× · PMID 35902958 · DOI 10.1186/s13287-022-03054-0
  2. Concise Review: Rational Use of Mesenchymal Stem Cells in the Treatment of Ischemic Heart Disease.
    Ward MR, Abadeh A, Connelly KA. · · 2018 · cited 65× · PMID 29665255 · DOI 10.1002/sctm.17-0210
  3. Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction.
    Chen Z, Chen L, Zeng C, Wang WE. · · 2018 · cited 40× · PMID 30622568 · DOI 10.1155/2018/7045245
  4. Locoregional delivery of stem cell-based therapies.
    Ng NN, Thakor AS. · · 2020 · cited 24× · PMID 32522806 · DOI 10.1126/scitranslmed.aba4564
  5. Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI trial.
    Xu JY, Qian HY, Huang PS, Xu J, et al · · 2019 · cited 9× · PMID 31829095 · DOI 10.2217/rme-2019-0024
  6. Stem cell therapy for patients with acute myocardial infarction: a systematic review of clinical trials.
    Mahram H, Khalafi V, Arman A, Mirhosseini SA, et al · · 2025 · PMID 41469916 · DOI 10.1186/s13287-025-04882-6

Verify or expand the search:

Other trials of Atorvastatin

Trials testing the same drug.

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03047772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing